Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA says this weight loss drug shortage is over
Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight
A turbulent series of events around the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around how the FDA maintains its list of drug shortages.
FDA says this weight loss drug shortage is over, but patients worry about cost and availability
Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.
Women turn to weight loss drugs in menopause: What to know about the benefits and risks
Losing weight in menopause can help with the severity of other menopause symptoms like hot flashes and night sweats, according to Shepherd. The average age for menopause, when your periods stop permanently, is 52, according to the U.S. Office on Women's Health. Menopause is reached after it has been a full year since your last period.
Teenagers Are Taking New Weight-Loss Drugs, but the Science Is Far from Settled
Wegovy and similar weight-loss medications are becoming widely prescribed for teenagers with obesity, but little is known about their long-term effects
US FDA to reconsider decision barring compounded versions of Lilly weight loss drug
The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs.
Eli Lilly sues over knockoffs of signature weight loss drug, Zepbound
Eli Lilly sued three medical spas and online vendors for selling products that claim to contain the ingredient in its weight-loss medicine Zepbound.
MangoRx hits back at Eli Lilly’s weight loss drug copycat claims
MangoRx was responding to Eli Lily after the drugmaker sued it and two other medical spas and online vendors earlier this week for selling products claiming to contain tirzepatide
1d
FDA's Weight Loss Drug 'No Man's Land' Adds Risk for Compounders
Pharmacies currently making copycat versions of Eli Lilly’s tirzepatide face heightened exposure to state enforcement actions ...
2h
The Best Weight Loss Gummies to Burn Fat Safely & Naturally
While many people think attaining healthy weight loss is as easy as eating a balanced diet and engaging in regular physical ...
1d
Novo Nordisk asks FDA to block compounding pharmacies from making Ozempic copycats
Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own ...
1d
Novo Nordisk asks US to stop compounding pharmacies from making weight-loss drug copies
Oct 23 (Reuters) - Novo Nordisk (NOVOb.CO) on Tuesday asked the U.S. Food and Drug Administration to ban compounding ...
MassDevice
1d
Allurion submits weight loss balloon modules to the FDA for premarket approval
Allurion Technologies announced today that it submitted three modules for its weight loss balloon to the FDA for premarket ...
The Hill on MSN
10d
FDA will reconsider decision barring copycat versions of Lilly weight loss drug
The Food and
Drug
Administration (
FDA
) said it will reconsider its decision to remove Eli Lilly’s blockbuster
weight
...
AOL
12d
FDA shakes up weight loss market as Mounjaro shortage ends
Federal regulators shook up the booming
weight
loss
drug
marketplace ... Tirzepatide was first
approved
by the Food and
Drug
Administration (
FDA
) in 2022 and has no generic versions on the ...
BioSpace
1d
GLP-1 Prescriptions for Type 1 Diabetes Spike Despite Lack of FDA Approval: Study
While the regulator has not approved their use in type 1 diabetes, off-label prescribing for GLP-1 receptor agonists has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Food and Drug Administration
Ozempic
Novo Nordisk
Eli Lilly
Wegovy
Feedback